New research reveals how hypoxia-driven red blood cell adaptations can reshape glucose regulation, offering new insights into diabetes biology and potential therapeutic strategies.
Study: Red blood cells serve as primary glucose sinks to improve glucose tolerance at altitude. Image credit: nobeastsofierce / Shutterstock
In a recent study published in the journal Cellular Metabolismresearchers investigated whether red blood cells (RBCs) functions as a primary glucose sink under hypoxic conditions and thereby improves systemic glucose tolerance.
High altitude hypoxia and improved glucose control
Epidemiological observations show that populations living above 3,500 meters have lower rates of diabetes compared to those at sea level. Across Tibet, Peru, the United States, and Nepal, high-altitude communities consistently show lower fasting glucose levels and improved glucose tolerance. Even animals adapted to altitude show similar metabolic patterns. Despite reduced oxygen availability at high altitudes, blood glucose regulation appears enhanced, creating a physiological paradox.
Short-term hypoxia is known to stimulate glucose uptake in peripheral tissues. However, these effects are transient. The persistence of improved glucose control during chronic hypoxia suggests a deeper systemic adaptation. The biological mechanism underlying this prolonged effect remained unclear, prompting investigation into whether RBCs directly contribute to whole-body glucose disposal.
Normobaric Hypoxia Mouse Model Design
To isolate the impact of oxygen deprivation, the researchers used models of normobaric hypoxia in eight-week-old male mice. Animals were maintained in either normal conditions (21% oxygen) or hypoxic environments (8% oxygen, equivalent to altitudes above 5,000 meters) for up to three weeks. Blood glucose, body weight, glucose tolerance tests, and insulin tolerance tests were monitored longitudinally.
To determine whether increased RBC abundance affected glycemia, the researchers used two complementary strategies. Serial phlebotomy removed 15% of the total blood volume every three days to reverse hypoxia-induced erythrocytosis. In parallel experiments, packed RBCs from hypoxic or normoxic donor mice were transfused into normoxic recipients.
Glucose uptake was assessed using 2-deoxy-2-[18F] Fluoro-D-glucose positron emission tomography/computed tomography imaging and stable isotope tracing with uniformly labeled carbon-13 glucose and carbon-13 2-deoxy-D-glucose. Liquid chromatography-mass spectrometry quantified plasma glucose and intracellular metabolites. Glucose transporter assessed by flow cytometry 1 (GLUT1) and glucose transporter 4 (GLUT4) abundance in red blood cells. Proteomic and imaging approaches examined the localization and interactions of the glycolytic enzyme with the zone 3 protein under varying oxygen conditions.
Hypoxia rapidly lowers blood glucose independent of insulin
Chronic hypoxia significantly reduced basal blood glucose levels within two days of exposure. Glucose tolerance improved at 1, 2, and 3 weeks and persisted for more than a month after the mice were returned to normoxia. In contrast, insulin sensitivity was not improved and transiently decreased during hypoxia. The authors interpreted this decrease as a compensatory response to sustained hypoglycemia rather than enhanced insulin action.
Moderate hypoxia (11% oxygen) and intermittent hypoxia similarly improved fasting glucose and glucose tolerance, suggesting potential translational relevance. Hepatic gluconeogenesis did not account for the decreased blood glucose levels, indicating that increased glucose availability rather than decreased production was responsible for the observed hypoglycemia.
Red blood cells are recognized as the primary scavenger of glucose
Whole-body imaging revealed that classic glucose-consuming organs such as muscle, liver, heart, and brain accounted for only a minority of increased glucose uptake under hypoxia. This finding suggests the presence of another important compartment of glucose consumption.
During chronic hypoxia, RBC numbers nearly doubled. When erythrocytosis was reversed by serial phlebotomy, blood glucose levels normalized, but improvements in glucose tolerance disappeared. In contrast, transfusion of RBCs from hypoxic donors into normal mice induced hypoglycemia without exposure to hypoxia. These experiments demonstrated that increased red blood cell abundance was both necessary and sufficient to induce hypoglycemia associated with hypoxia in this model.
Enhanced cellular glucose uptake and transporter expression
In addition to increased cell number, individual red blood cells under hypoxia exhibited increased glucose uptake capacity. Stable isotope detection showed faster intracellular accumulation of phosphorylated 2-deoxy-D-glucose. Ex vivo experiments confirmed an approximately 2.5-fold increase in glucose uptake per cell.
Flow cytometry revealed upregulated expression of GLUT1 and GLUT4 in hypoxic RBCs. Biotin labeling experiments showed that newly synthesized RBCs substantially contributed to increased GLUT1 abundance, suggesting that erythropoiesis under hypoxia generates metabolically adapted RBC populations.
Metabolic rewiring through the Luebering-Rapoport junction
Metabolic tracing showed that glucose flux in hypoxic RBCs was redirected to the production of 2,3-bisphosphoglycerate via the Luebering-Rapoport shunt. Both levels and rates of isotopic labeling of 2,3-bisphosphoglycerate were elevated. This adaptation enhances the release of oxygen from hemoglobin to tissues while increasing glucose consumption. The authors noted that accurate quantitative flux measurements would require additional targeted analyses.
Low oxygen conditions displaced glyceraldehyde 3-phosphate dehydrogenase (GAPDH) by its inhibitory binding to the zone 3 membrane protein, thereby increasing glycolytic flux. This molecular mechanism provided a structural explanation for the accelerated glucose metabolism in red blood cells under hypoxia.
Therapeutic Effects in Diabetes Models
Hypoxia exposure and hypoxic RBC transfusion ameliorated hyperglycemia in mouse models of type 1 diabetes, enhancing glucose tolerance despite insulin deficiency. In a high-fat diet model of type 2 diabetes, treatment with a pharmacological agent (HypoxyStat) that increases hemoglobin oxygen affinity and induces tissue hypoxia improved glycemia and glucose tolerance without immediate RBC transfusion.
These findings suggest that targeting erythrocyte metabolism or safely mimicking hypoxia-induced erythrocyte adaptations may offer therapeutic approaches for hyperglycemic conditions.
Red blood cells as regulators of systemic glucose metabolism
This study identifies red blood cells as previously unrecognized regulators of systemic glucose metabolism. Hypoxia increases red blood cell production and enhances per-cell glucose utilization, allowing red blood cells to act as an important glucose sink independent of insulin signaling. By metabolizing glucose through glycolysis and Luebering-Rapoport efflux, RBCs improve oxygen delivery and lower circulating glucose levels.
The findings expand the understanding of whole-body glucose homeostasis and suggest potential therapeutic strategies for type 1 and type 2 diabetes. Modulating red blood cell metabolism or exploiting hypoxic adaptations could represent novel avenues in the management of metabolic diseases.
